Epion Therapeutics, Inc.
Epion Therapeutics is dedicated to developing minimally-invasive treatments for ectatic corneal diseases such as keratoconus. Their innovative EpiSmart approach is designed to provide a transformative, epithelium-on cross-linking system that allows for early intervention, rapid recovery, and improved safety for patients worldwide. The company's mission is to elevate the standard of care in corneal strengthening and preserve vision through advanced research, clinical trials, and innovative medical devices.
Industries
Nr. of Employees
small (1-50)
Epion Therapeutics, Inc.
Patents
Ophthalmic treatment solution delivery devices and delivery augmentation methods
US-11931291-B2
View Details
Ophthalmic treatment solution delivery devices and delivery augmentation methods
US-11931291-B2
View DetailsProducts
Minimally‑invasive epithelium‑on corneal cross‑linking system (investigational)
An investigational drug–device combination intended to strengthen the corneal stroma via transepithelial riboflavin delivery and controlled UVA illumination without removing the corneal epithelium.
Minimally‑invasive epithelium‑on corneal cross‑linking system (investigational)
An investigational drug–device combination intended to strengthen the corneal stroma via transepithelial riboflavin delivery and controlled UVA illumination without removing the corneal epithelium.
Services
Sponsorship and operational management of randomized controlled multicenter clinical trials (including Phase 2 and Phase 3) to generate safety and efficacy data for registration.
Laboratory and independent-laboratory testing to quantify stromal drug loading, compare delivery methods, and support translational development.
Sponsorship and operational management of randomized controlled multicenter clinical trials (including Phase 2 and Phase 3) to generate safety and efficacy data for registration.
Laboratory and independent-laboratory testing to quantify stromal drug loading, compare delivery methods, and support translational development.
Expertise Areas
- Corneal cross-linking development
- Drug–device combination product development
- Transepithelial ocular drug delivery
- Clinical trial management for ophthalmic interventions
Key Technologies
- Riboflavin‑based photochemical corneal cross-linking
- Transepithelial (epithelium-on) drug delivery
- Topical applicator systems for ocular drug loading
- UVA illumination systems for photochemical therapy
News & Updates
Epion Therapeutics has announced the full enrollment of patients in their Phase 3 clinical trials for the EpiSmart Epithelium-On Cross-Linking System, supporting its potential registration and future use in treating keratoconus and ectasia.
The latest newsletter highlights Epion Therapeutics’ Phase 3 trials of the EpiSmart Epithelium-On Cross-Linking System, emphasizing the progress and potential of this innovative treatment.
An update on the clinical study enrollment for keratoconus treatment, indicating the importance of early diagnosis and intervention.
A review of current research on corneal cross-linking (CXL) and its role in slowing keratoconus progression, highlighting the importance of early diagnosis.
Epion Therapeutics secured a new U.S. patent for its light therapy device, a core component of the EpiSmart™ Epithelium-On Cross-linking System.
The company announced the full enrollment of patients in their Phase 3 clinical trials for EpiSmart, supporting future registration and approval.
Epion Therapeutics has announced the full enrollment of patients in their Phase 3 clinical trials for the EpiSmart Epithelium-On Cross-Linking System, supporting its potential registration and future use in treating keratoconus and ectasia.
The latest newsletter highlights Epion Therapeutics’ Phase 3 trials of the EpiSmart Epithelium-On Cross-Linking System, emphasizing the progress and potential of this innovative treatment.
An update on the clinical study enrollment for keratoconus treatment, indicating the importance of early diagnosis and intervention.
A review of current research on corneal cross-linking (CXL) and its role in slowing keratoconus progression, highlighting the importance of early diagnosis.
Epion Therapeutics secured a new U.S. patent for its light therapy device, a core component of the EpiSmart™ Epithelium-On Cross-linking System.
The company announced the full enrollment of patients in their Phase 3 clinical trials for EpiSmart, supporting future registration and approval.